PT-141 (Bremelanotide) Dosing in Renal Impairment

What Is Bremelanotide and How Does It Work?

Bremelanotide is a synthetic cyclic peptide that activates melanocortin-4 receptors (MC4R) in the central nervous system to increase sexual desire. The FDA approved it in June 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. It is the only on-demand injectable treatment for this indication.

Unlike phosphodiesterase-5 inhibitors that act on vascular smooth muscle, bremelanotide works upstream in the hypothalamic circuits that regulate sexual motivation [2]. The drug binds MC1R, MC3R, MC4R, and MC5R, but the pro-sexual effect is attributed primarily to MC4R agonism in the medial preoptic area and paraventricular nucleus [3]. This central mechanism explains why its clearance profile through the kidneys matters clinically. A peptide that depends on renal elimination for roughly two-thirds of its clearance will accumulate when glomerular filtration drops.

Administered as a 1.75 mg subcutaneous injection 45 minutes before anticipated sexual activity, bremelanotide reaches peak plasma concentration (Tmax) at approximately 1 hour post-dose [1]. Bioavailability approaches 100% by the subcutaneous route. The terminal half-life averages 2.7 hours in volunteers with normal renal function, and the drug undergoes hydrolysis rather than cytochrome P450 metabolism [1]. These pharmacokinetic features set the stage for understanding how kidney disease alters drug exposure.

FDA Pharmacokinetic Data by Renal Function Category

The prescribing information for Vyleesi includes a dedicated renal impairment pharmacokinetic study that stratified subjects by eGFR [1]. That study is the primary basis for current dosing guidance. Here is what the data showed.

In subjects with mild renal impairment (eGFR 60 to 89 mL/min/1.73 m²), bremelanotide AUC and Cmax were not meaningfully different from those in subjects with normal renal function [1]. No dose adjustment is needed. In moderate renal impairment (eGFR 30 to 59), AUC increased modestly, but the FDA concluded the change did not warrant a formal dose reduction [1]. Patients in this range can receive the standard 1.75 mg dose, though clinicians should watch for nausea and blood pressure changes more closely.

Severe renal impairment tells a different story. In subjects with eGFR 15 to 29, bremelanotide AUC increased by approximately 70% compared to matched controls with normal kidney function [1]. Cmax also rose. The FDA labeling states that Vyleesi "is not recommended" in patients with severe renal impairment because of this exposure increase [1]. The concern is not nephrotoxicity per se but amplified systemic effects: more pronounced nausea, greater transient hypertension, and more intense facial flushing.

No data exist for patients on hemodialysis or peritoneal dialysis. The molecular weight of bremelanotide (1,025 Da) suggests it could be partially cleared by high-flux dialysis membranes, but this has not been tested [4]. Until pharmacokinetic data become available, the prudent approach is to avoid prescribing bremelanotide to patients with end-stage renal disease (ESRD).

Why Renal Clearance Matters for a Peptide Drug

Roughly 64.8% of a bremelanotide dose is recovered in urine, mostly as metabolites generated by enzymatic hydrolysis of the peptide bonds [1]. The remaining fraction is eliminated through feces and other minor routes. When the glomerular filtration rate falls, urinary clearance slows and the drug lingers in the systemic circulation longer.

This is not unique to bremelanotide. Many peptide therapeutics face the same challenge. Exenatide (Byetta), another subcutaneous peptide, carries a similar renal impairment warning because its clearance drops 36% in moderate CKD and 64% in ESRD [5]. The pattern is predictable: peptides too large for tubular reabsorption but small enough for glomerular filtration accumulate as nephron mass declines.

For bremelanotide specifically, the 70% AUC increase in severe CKD translates to a drug exposure roughly equivalent to giving a 3 mg dose to someone with normal kidneys. The RECONNECT trials tested 1.75 mg against placebo and did not evaluate higher fixed doses in the phase 3 program [6]. Clinicians therefore have no controlled safety data at the exposure levels that severe CKD patients would experience, which is the core reason the FDA label discourages use in this group.

The RECONNECT Trials: Efficacy Context for Dosing Decisions

The RECONNECT program consisted of two randomized, double-blind, placebo-controlled trials enrolling 1,247 premenopausal women with generalized acquired HSDD [6]. Participants self-administered bremelanotide 1.75 mg or placebo subcutaneously as needed over 24 weeks.

In pooled results, bremelanotide-treated patients reported a statistically significant increase in satisfying sexual events (SSEs) compared to placebo: a mean increase of 1.0 SSE per month over baseline versus 0.4 for placebo [6]. The co-primary endpoint, the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score, decreased by 1.0 point versus 0.6 points for placebo (P<0.001) [6].

Nausea was the most common adverse event, affecting 40% of bremelanotide-treated patients versus 1% on placebo [6]. About 13% of women in the active arm experienced flushing. Mean systolic blood pressure rose approximately 3 mmHg within 2 to 3 hours of dosing and returned to baseline by 12 hours [1]. These adverse effects are dose-exposure dependent. A patient with severe CKD experiencing 70% higher drug levels would face a proportionally greater burden of these side effects.

The trials excluded women with uncontrolled hypertension (defined as systolic ≥140 mmHg or diastolic ≥90 mmHg) and those with significant renal disease [6]. This exclusion means the RECONNECT data cannot be directly extrapolated to CKD populations. Prescribers treating women who have both HSDD and kidney disease are working outside the studied population.

Blood Pressure Considerations in CKD Patients

The transient hypertensive effect of bremelanotide deserves particular attention in patients with chronic kidney disease. CKD patients already carry elevated cardiovascular risk. The 2021 KDIGO guideline for blood pressure management in CKD recommends a systolic target <120 mmHg for most patients with CKD, measured by standardized office technique [7].

A 3 mmHg mean systolic rise may sound trivial, but it represents an average. Some patients in the RECONNECT trials experienced larger increases. The FDA label notes that individual systolic rises of ≥20 mmHg were observed [1]. In a CKD patient already near their target ceiling, even a transient spike could carry consequences, particularly in those with CKD stages 4 to 5 who have reduced vascular compliance and higher baseline cardiovascular event rates [7].

Bremelanotide is contraindicated in patients with uncontrolled hypertension and in those with known cardiovascular disease [1]. For CKD patients with well-controlled blood pressure, the label permits use in mild-to-moderate impairment, but the prescriber should verify that home blood pressure readings remain stable after the first dose. As the Endocrine Society's 2019 guideline on female sexual dysfunction states, "pharmacotherapy for HSDD should be individualized, weighing benefits against cardiovascular and other risks" [8].

Practical Dosing Algorithm by eGFR

A stepwise approach helps clinicians decide whether bremelanotide is appropriate based on kidney function.

eGFR ≥60 mL/min/1.73 m² (CKD stages 1 to 2)

Prescribe the standard 1.75 mg subcutaneous dose. No modifications needed. Counsel on nausea (consider ondansetron pretreatment if prior GI sensitivity) and transient blood pressure elevation [1]. Limit use to once per 24 hours and no more than 8 doses per month.

eGFR 30 to 59 mL/min/1.73 m² (CKD stage 3)

The 1.75 mg dose remains appropriate per the FDA label [1]. Check blood pressure before and 2 hours after the first dose. If systolic rises >10 mmHg or exceeds 140 mmHg, reassess the risk-benefit balance. Monitor for more pronounced nausea and flushing. Repeat eGFR at regular intervals because progressive CKD could shift the patient into a higher-risk category.

eGFR 15 to 29 mL/min/1.73 m² (CKD stage 4)

The FDA recommends avoiding bremelanotide in this range due to the ~70% increase in AUC [1]. If a clinician and patient decide to proceed after shared decision-making, no reduced-dose formulation is commercially available. The auto-injector delivers a fixed 1.75 mg dose [1]. Compounding a lower dose would be off-label and would require verification of peptide stability, sterility, and accurate fill volume.

eGFR <15 or Dialysis (CKD stage 5 / ESRD)

Do not prescribe. No pharmacokinetic data exist for this population. The drug's clearance mechanism suggests significant accumulation, and the cardiovascular risk profile of ESRD patients makes the transient hypertensive effect particularly concerning [7].

Monitoring Recommendations for Prescribers

For any patient with CKD who receives bremelanotide, the following monitoring framework applies.

Before prescribing, confirm the eGFR is ≥30 mL/min/1.73 m² and has been measured within the past 3 months. Obtain a baseline blood pressure reading. Review the medication list for other drugs that raise blood pressure or slow renal clearance of peptides, such as NSAIDs and calcineurin inhibitors.

After the first dose, ask the patient to measure blood pressure at home approximately 2 hours post-injection and report the reading at follow-up. If nausea is severe (grade 2 or higher on CTCAE criteria), consider ondansetron 4 mg orally 30 minutes before the next bremelanotide dose [1]. The FDA label notes that 40% of patients experience nausea, and in the setting of higher drug exposure from impaired clearance, this rate may climb.

At follow-up visits (every 3 to 6 months), recheck eGFR. CKD is progressive in many patients. A woman who starts bremelanotide at eGFR 45 may decline to eGFR 28 within a year, at which point the drug should be discontinued per the FDA recommendation [1].

Off-Label Use in Men: Renal Dosing Extrapolation

Bremelanotide is FDA-approved only for HSDD in premenopausal women, but off-label use in men with erectile dysfunction has been explored in early-phase trials [9]. A phase 2b study of intranasal bremelanotide in men with ED showed improvements in erectile function scores, though the intranasal formulation was ultimately not pursued due to blood pressure concerns [9].

Men considering off-label subcutaneous bremelanotide face the same renal dosing constraints as women. The pharmacokinetic study in the FDA label did not stratify by sex, but the renal elimination fraction (64.8%) is a drug property, not a sex-dependent variable [1]. Men with CKD stage 4 or 5 should avoid bremelanotide for the same reasons that apply to women. Men with CKD stages 1 to 3 who use bremelanotide off-label should follow the same blood pressure and eGFR monitoring protocol described above.

The American Urological Association's 2018 guideline on erectile dysfunction notes that "off-label pharmacotherapy should be accompanied by informed consent documenting the lack of FDA approval for the specific indication" [10]. This documentation takes on added weight when renal impairment complicates the dosing picture.

Drug Interactions Relevant to Renal Patients

CKD patients often take multiple medications. Several interactions with bremelanotide warrant attention.

Bremelanotide slows gastric emptying [1]. This effect can delay the absorption of orally administered drugs. The FDA label specifically warns that bremelanotide may reduce the rate and extent of absorption of concomitant oral medications and recommends avoiding co-administration with oral naltrexone or oral indomethacin [1]. For CKD patients already taking phosphate binders, oral iron supplements, or calcineurin inhibitors with narrow therapeutic windows, the delayed gastric emptying could alter drug levels unpredictably.

ACE inhibitors and angiotensin receptor blockers, standard therapy in proteinuric CKD per the 2021 KDIGO guideline [7], have not shown direct pharmacokinetic interactions with bremelanotide. The theoretical concern is additive hemodynamic effects. A patient taking an ARB at maximum dose who then uses bremelanotide might experience a transient blood pressure rise on top of an already labile baseline. Clinical judgment should guide whether the combination is safe in a given patient.

Bremelanotide does not inhibit or induce cytochrome P450 enzymes at clinically relevant concentrations [1]. This simplifies the interaction picture compared to many small-molecule drugs used in sexual medicine (e.g., sildenafil, which interacts with CYP3A4 inhibitors). The primary interaction risk with bremelanotide is pharmacodynamic, not pharmacokinetic: blood pressure effects and gastric motility changes.

When to Consider Alternative Treatments

If renal impairment rules out bremelanotide, two FDA-approved alternatives exist for HSDD in premenopausal women: flibanserin (Addyi) and, in some cases, testosterone therapy under specialist guidance.

Flibanserin is hepatically metabolized (CYP3A4, CYP2C19) and does not depend on renal clearance [11]. The prescribing information for Addyi states that no dose adjustment is needed in renal impairment of any severity [11]. The tradeoff is that flibanserin requires daily dosing, carries a boxed warning for hypotension and syncope with alcohol, and showed modest efficacy in clinical trials (approximately 0.5 additional SSEs per month versus placebo in the SNOWDROP trial, N=1,087) [12].

For men with ED and CKD, phosphodiesterase-5 inhibitors remain first-line. Sildenafil requires dose reduction in severe CKD (starting dose 25 mg), and tadalafil should begin at 5 mg with careful titration [13]. These drugs have decades of post-marketing data in CKD populations, which bremelanotide lacks.

The decision tree is straightforward: if eGFR is ≥30, bremelanotide can be prescribed at the standard dose with monitoring. If eGFR is <30, redirect to flibanserin for women with HSDD or to PDE5 inhibitors for men with ED, adjusting those drugs' doses for renal function as their respective labels direct.